Zusammenfassung
Hintergrund Subretinale Blutungen bei altersabhängiger Makuladegeneration (AMD) verursachen gewöhnlich einen akuten Sehverlust mit einer reduzierten Prognose. Um einen stärkeren Netzhautschaden durch das Blut zu verhindern und um die zugrundeliegende choroidale Neovaskularisation (CNV) gegebenenfalls einer Laserbehandlung zugänglich zu machen, muss die subretinale Blutung aus dem Bereich der choroidalen Neovaskularisation entfernt werden. Dieses kann durch die intravitreale Injektion von Gewebe-Plasminogen-Aktivator (tPA) und Gas erreicht werden.
Patienten und Methode Gewebe-Plasminogen-Aktivator (tPA; 40 μg in 400 μl BSS) und SF6 -Gas (0,75ml) wurde bei acht konsekutiven Patienten in den Glaskörperraum injiziert, um die subretinale Blutung zu verflüssigen und aus dem Makulabereich zu verdrängen. Die Patienten beschrieben Sehprobleme zwischen einem und 16 Tage (im Mittel neun Tage).
Ergbnisse Bei allen Patienten konnten postoperativ eine Verflüssigung und eine Verlagerung der Blutung aus dem Makulabereich erreicht werden. Während der ersten Woche nach Operation zeigte sich ein signifikanter Visusanstieg im Gesamtkollektiv, ophthalmoskopisch zeigte sich allerdings nur eine geringe Reduktion der Blutung. Bei einem Patienten konnte anschließend eine Laserkoagulation der zugrundeliegenden CNV durchgeführt werden. Bei den anderen Patienten wurde keine Laserkoagulation aufgrund der subfovealen Lage der okkulten Membran oder wegen einer bereits bestehenden disziformen Narbe durchgeführt. Bei einem Patienten kam es nach der Operation zu einer persistierenden Glaskörperblutung. Als ernste Komplikation trat bei einem Patienten eine Endophthalmitis auf.
Zusammenfassung Die intravitreale Gabe von tPA und Gas bei subretinaler Blutung im Rahmen einer altersabhängigen Makuladegeneration kann innerhalb der ersten Woche zu einem signifikanten Visusanstieg führen. Eine weitgehende Verlagerung der Blutung aus dem Funduszentrum konnte zwar erreicht werden, doch ist eine Abgrenzung zum Spontanverlauf schwierig. Hier müsste eine kontrollierte Studie weitere Aufschlüsse liefern. Eine anschließende Laserkoagulation konnte erfahrungsgemäß aufgrund von Ausschlusskriterien bei AMD nur selten durchgeführt werden.
Background Subretinal hemorrhage in age related macular degeneration (AMD) usually causes acute visual loss and is associated with poor visual prognosis. In order to prevent retinal damage and to perform laser treatment of the underlying choroidal neovascularization (CNV) the subretinal hemorrhage has to be removed from the macular region. This could be achieved by intravitreal injection of tissue plasminogen activator (tPA) and gas.
Patients and methods In 8 consecutive patients, suffering from a massive macular hemorrhage (duration of visual problems: mean 9 days), tissue plasminogen activator (tPA) (40 μg in 400 μl BSS) and SF6 -gas (0.75 ml) was transsclerally injected into the vitreous cavity to achieve liquification and displacement of the hemorrhage.
Results In all patients liquification and displacement of the hemorrhage out of the macular region was achieved during follow up. During the first week after operation a significant increase of visual acuity was noticed in all patients, however ophthalmoscopically there was just little reduction of the hemorrhage in the foveolar area. After successful removal of the blood the choroidal neovascularization was treated successfully by laser coagulation in one patient. No laser treatment was performed in the other patients because of the subfoveal location of the neovascularisation or because of disciform scar. Visual acuity increased 4 lines after surgery. In one case the procedure was complicated by a persistent vitreous hemorrhage and vitrectomy had to be performed in another patient due to an endophthalmitis.
Conclusion Intravitreal injection of tPA assisted gas displacement of subretinal hemorrhage due to AMD leads to a significant increase of visual acuity during the first week after operation. Although a nearly complete removal of the hemorrhage out of the macular area could be achieved, it was difficult to differentiate this from the spontaneous course. Laser photocoagulation could be performed in only few cases.
Schlüsselwörter
Makuladegeneration - choroidale Neovaskularisation - subretinale Hämorrhagie - tPA
Key words
macular degeneration - choroidal neovascularization - subretinal hemorrhage - tPA
Literatur
1 Manuskript eingereicht am 17. 9. 99 und in der vorliegenden Form angenommen am 23. 11. 99.
01
Benett S R, Folk J C, Blodi C F, Klugmann M.
Factors prognostic of visual outcome in patients with subretinal haemorrhage.
Am J Ophthalmol.
1990;
109
33-34
02
Bergink G J, Deutman A F, van den Brock J FCM, Dal W AJ, van der Maazen R WM.
Radiation therapy for subfoveal choroidal membranes in age-related macular degeneration.
Graefe's Arch Clin Exp Ophthalmol.
1994;
232
591
03
Bird A C, Bressler N M, Bressler S B et al.
An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM Epidemiological Study Group.
Surv Ophthalmol.
1995;
39
367-374
04
Boone D E, Boldt H C, Ross R D, Folk J C, Kimura A E.
The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model.
Retina.
1996;
16
518-524
05
Chakravarthy U, Houston R F, Archer D B.
Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study.
Br J Ophthalmol.
1993;
77
265
06
Claes C, Zivojnovic R.
Subretinal hemorrhage removal.
Bull Soc Ophthalmol.
1993;
250
85-88
07
Coll G E, Sparrow J R, Marinovic A, Chang S.
Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage.
Retina.
1995;
15
319-326
08
Collen D, Lijnen H R.
Tissue type plasminogen activator: mechanism of action and thrombolytic properties.
Haemostasis.
1986;
30
25-32
09
Collen D, Stussen J M, Marafino B J Jr, et al.
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
J Pharmacol Exp Ther.
1984;
231
146-152
10
deJuan E Jr, Machemer R.
Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration.
Am J Ophthalmol.
1988;
105
25-29
11
Dellaporta A N.
Evacuation of subretinal hemorrhage.
Int Ophthalmol.
1994;
18
25-3124
12
Dellaporta A N.
Retinal damage from subretinal hemorrhage.
Am J Ophthalmol.
1983;
95
568-570
13
Elman M J, Quinlan P, Fine S L et al.
Thrombolytic therapy for central vein occlusion.
Invest Ophthalmol Vis Sci.
1988;
29 (suppl)
68
14
Ferris F L, Fine S L, Hyman L.
Age-related macular degeneration and blindness due to neovascular maculopathy.
Arch Ophthalmol.
1984;
102
1640
15
Fung W E.
Interferon alpha-2a for the treatment of age-related macular degeneration.
Am J Ophthalmol.
1991;
112
349
16
Gibson J M, Rosenthal A R, Lavery J.
A study of the prevalence of eye disease in the elderly in an English community.
Trans Ophthalmol Soc UK.
1985;
104
196
17
Glatt H, Machemer R.
Experimental subretinal hemorrhage in rabbits.
Am J Ophthalmol.
1982;
94
762-773
18
Googe J M, Hirose T, Apple D J, Melgen S.
Vitreous hemorrhage secondary to age related macular degeneration.
Surv Ophthalmol.
1987;
32
123-130
19
Haab O.
Erkrankungen der Macula lutea.
Centralblatt für praktische Augenheilkunde.
1885;
9
383
20
Hanscom T A, Diddie K R.
Early surgical drainage of macular subretinal hemorrhage.
Arch Ophthalmol.
1987;
105
1722-1723
21
Haut J.
Treatment of senile macular degeneration.
Arch Ophthalmol.
1969;
29
909
22
Hesse L, Schmidt J, Kroll P.
Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas.
Graefes Arch Clin Exp Ophthalmol.
1999;
237
273-277
23
Ibanez H E, Williams D F, Thomas M A, Ruby A J, Meredith T A, Boniuk I, Grand M G.
Surgical management of submacular hemorrhage. A series of 47 consecutive cases.
Arch Ophthalmol.
1995;
113
62-69
24
Irvine W D, Johnson M W, Hernandez E, Olsen K R.
Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes.
Arch Ophthalmol.
1991;
109
718-722
25
Jaffe G J, Abrams G W, Williams G A, Han D P.
Tissue plasminogen activator for post-vitrectomy fibrin formation.
Ophthalmology.
1990;
97
184-189
26
Jaffe G J, Lewis H, Han D P, Williams G A, Abrams G W.
Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.
Am J Ophthalmol.
1989;
108
170-175
27
Johnson M W, Olsen K R, Hernandez E, Irvine W D, Johnson R N.
Retinal toxicity of recombinant tissue plasminogen activator in the rabbit.
Arch Ophthalmol.
1990;
108
259-263
28
Johnson M W, Olsen K R, Hernandez E.
Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal haemorrhage.
Ophthalmology.
1992;
99
515-521
29
Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsuda H, Yuasa T.
Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid.
Am J Ophthalmol.
1996;
121
267-275
30
Klein R, Klein B EK, Linton K LP.
Prevalence of age-related maculopathy. The Beaver Dam Eye Study.
Ophthalmology.
1992;
99
933-943
31
Lewis H, Resnick S C, Flannery J G, Straatsma B R.
Tissue plasminogen activator treatment of experimental subretinal hemorrhage.
Am J Ophthalmol.
1991;
111
197-204
32
Lewis H.
Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage.
Am J Ophthalmol.
1994;
118
559-568
33 Lewis H. Management of submacular hemorrhage. In: Lewis H, Ryan SJ (eds). Medical and Surgical Retina: Advances, Controversies and Management. C.V. Mosby, St. Louis; 1993: 54-62
34
Lim J I, Drews-Botsch C, Sternberg P Jr, Capone A Jr, Aaberg T M Sr.
Submacular hemorrhage removal.
Ophthalmology.
1995;
102
1393-1399
35
Macular Photocoagulation Study Group.
Argon laser photocoagulation for neovascular maculopathy after five years.
Arch Ophthalmol.
1991;
109
1109-1114
36
Marmor M F, Negi A, Maurice D M.
Kinectics of macromolecules injected into the subretinal space.
Exp Eye Res..
1985;
40
687-696
37
Moon J, Chung S, Myong Y, Park C, Baek N, Rhee S.
Treatment of postcataract fibrinous membranes with tissue plasminogen activator.
Ophthalmology.
1992;
99
1256-1259
38
Moorfields Macular Study Group.
Argon laser photocoagulation for senile macular degeneration: a single blind randomized trial.
Br J Ophthalmol.
1982;
66
745-753
39
Newsome D A, Swartz M, Leone N C, Elston R C, Miller E.
Oral zinc in macular degeneration.
Arch Ophthalmol.
1988;
106
192
40
Ohji M, Saito Y, Hayashi A, Lewis J M, Tano Y.
Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator.
Arch Ophthalmol.
1998;
116
1326-32
41
Peyman G A, Nelson N C Jr, Alturki W, Blinder K J, Paris C L, Desai U R, Harper C A 3d.
Tissue plasminogen activating factor assisted removal of subretinal hemorrhage.
Ophthalmic Surg.
1991;
22
575-582
42
Rogers S D, Riemersma L B, Clements S B.
Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
Pharmacotherapy.
1987;
7
111-121
43
Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte T J, Birngruber R.
Vascular treating in photodynamic occlusion of subretinal vessels.
Ophthalmology.
1994;
101
1953-1961
44
Seddon J M, Ajani U A, Sperduto R D, et al.
Dietary caretenoids, vitamin A, C, and E, and advanced age-related macular degeneration.
Jama.
1994;
272
1413
45
Snyder R W, Sherman M D, Allison R W.
Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty.
Am J Ophthalmol.
1990;
109
483-384
46
Sochor G E, Daniel F, Decrinis F, Pilger E.
Fibrinolys (rtPA) als Therapie bei akuten retinalen Gefäßverschlüssen.
Spektrum Augenheilkd.
1994;
8
176-178
47
Takeuchi A, Kricorian G, Yao X-Y, Kenny J W, Marmor M F.
The raste and source of albumin entry into saline-filled experimental retinal detachments.
Invest ophthalmol Vis Sci.
1994;
35
3792-3798
48
The Eye Disease Case-Control Study Group.
Risk factors for neovascular age-related macular degeneration.
Arch Ophthalmol.
1992;
110
1701
49
Toth C A, Morse L S, Hijelmeland L M, Landers M B.
Fibrin directs early retinal damage after experimental subretinal hemorrhage.
Arch Ophthalmol.
1991;
109
723-729
50
Tripathi R C, Tripathi B J, Park J K, Quaranta L, Steinsapir K, Lehman E, Ernest J T.
Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures.
Am J Ophthalmol.
1991;
111
247-248
51
Vander J F, Federman J L, Greven C, Slusher M M, Gabel V P.
Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration.
Ophthalmology.
1991;
98
23-27
52
Wade E C, Flynn H W Jr, Olson K R, Blumenkranz M S, Nicholson D H.
Subretinal hemorrhage management by pars plana vitrectomy and internal drainage.
Arch Ophthalmol.
1990;
108
973-978
53
Wedrich A, Menapace R, Muhlbauer-Ries E.
The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.
Int Ophthalmol.
1994;
18
277-280
54
Williams G A, Lambrou F H, Jaffe G J, Snyder R W, Green G D, Devenyi R G, Abrams G W.
Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
Arch Ophthalmol.
1988;
106
1055-1058
55 Wilson H. Intravitreal gas and tPA: An outpatient procedure for subretinal hemorrhage. Vail Vitrectomy Meeting 1996